Jardine Matheson Holdings Limited (JAR)
London Exchange · UK · prices in USD · close of 15 Oct 2026
Key indicators
| Last close | USD 62.50 |
|---|---|
| 52-week range | 57.20 – 82.50 |
| Return, 1 month / 3 months | +0.0% / +0.0% |
| Return, 1 year / 3 years | +0.0% / +3.7% |
| Trend | Uptrend |
| RSI (14) | 52 |
| Volatility (1 year) | 4.3% |
| Worst drawdown (1 year) | -2.8% |
| Average daily value traded | 0.06M USD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Jardine Matheson Holdings is a diversified conglomerate focused on Asia, based in Bermuda and run from Hong Kong. Through its subsidiaries it operates hotels under Mandarin Oriental, commercial property through Hongkong Land, food retailing and convenience stores through Dairy Farm, and motor vehicle distribution and engineering businesses, largely via Jardine Cycle & Carriage and its stake in Astra. Its customers span consumers, retailers, property tenants and industrial clients across Asian markets and beyond.
On this site Jardine Matheson Holdings Limited appears as a stock on the London Exchange (UK), code JAR, with prices in US dollars (USD). Our dividend records, which start in 2019, show payments in 6 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Jardine Matheson Holdings Limited (JAR) trades on the London Exchange in UK. It last closed at USD 62.50 on 15 October 2026.
Its price-based Market X-Ray is 61 out of 100 (a fair price profile), ranking 1,192 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 0.0% and over the last three months it rose 0.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 64 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 0.1% | ||
| From 52-week high | 0.0% | ||
| Momentum | 48 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | 0.0% | ||
| 6-month return | 0.0% | ||
| 12-month return, skipping the last month | 0.0% | ||
| Stability (higher is calmer) | 98 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 4.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -2.8% | ||
| Liquidity | 18 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.06M USD | ||
| Zero-volume days | 73.3% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 3 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Momentum: Lagging most stocks on this exchange.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +0.0% |
|---|---|
| 1 month | +0.0% |
| 3 months | +0.0% |
| 6 months | +0.0% |
| 1 year | +0.0% |
| 3 years | +3.7% |
| 5 years | +11.2% |
Signals
| 50-day / 200-day average | 62.49 / 62.46 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.69 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 22 Aug 2024 | USD 0.6000 |
| 21 Mar 2024 | USD 1.6500 |
| 17 Aug 2023 | USD 0.6000 |
| 16 Mar 2023 | USD 1.6000 |
| 18 Aug 2022 | USD 0.5500 |
| 17 Mar 2022 | USD 1.5600 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.